Clinical trial NCT05676138: PK and PD of Antibiotics for Treatment of Mycobacterium Abscessus Pulmonary Disease
Official title: Pharmacokinetics and Pharmacodynamics of Multidrug-regimens for Mycobacterium Abscessus Pulmonary Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Nontuberculous Mycobacterial Pulmonary Infection
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2023-01-09
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with M. abscessus pulmonary disease, who receive conventional antibiotic treatment based on the currently recommended guideline.

Brief summary: Investigating the PK and PD indices in patients with M. abscessus complex-PD who will be treated with a currently recommended regimen, minimum inhibitory concentrations of organism, and their relation with clinical outcomes

Detailed description: Nontuberculous mycobacteria (NTM), consisting of more than 200 mycobacteria other than M. tuberculosis and M. leprae, is an environmental organism, which can be isolated from soil, dust and water. NTM can cause chronic diseases in human and the most common manifestation is pulmonary disease (PD) . During the last decades, the burden of NTM-PD in rapidly increasing in global. In South Korea, the incidence has increased from 1.0 per 100,000 population in 2003 to 17.9 per 100,00 population in 2016.

M. abscessus complex is a group of rapidly growing mycobacteria (RGM). M. abscessus complex can be divided into three subspecies: M. abscessus subspecies abscessus (hereafter, referred to as M. abscessus), M. abscessus subspecies massiliense (M. massiliense), and M. abscessus subspecies bolletii (M. bolletii). Among the RGMs, M. abscessus complex is the most common pathogen for respiratory infection. With its distinctive surface properties and type VII secretion system (ESX-4), M. abscessus complex can cause progressive infection in patients with structural lung diseases such as cystic fibrosis.

Treatment of M. abscessus complex is extremely difficult. M. abscessus complex is generally resistant to most classes of antibiotics due to decreased cell wall permeability, induction of efflux pumps, and modification of drug targets. Especially, the presence of function erm(41) gene in M. abscessus confers inducible resistance to macrolide, which is the core drug of NTM-PD. As a result, multidrug regimens including at least three or four active drugs based on in vitro susceptibility are recommended for M. abscessus complex-PD.

Even though these complex and intensified treatments are administered in real clinical practice, the optimal drugs, dosage and duration of therapy are still not understood. Moreover, treatment outcomes are still unsatisfactory. According to the dataset from 303 patients with M. abscessus complex-PD, the treatment success rates were 33.0% for M. abscessus and 56.7% for M. massiliense, respectively. The unfavorable outcomes of currently recommended regimens are partly explained by an incomplete understanding of the relationship between pharmacokinetics (PK) of drugs used, in vitro susceptibility and treatment outcomes. To improve treatment outcomes, it should be preceded to figure out the potential efficacy of currently recommended regimens for M. abscessus complex-PD.

This will be performed as a prospective pharmacokinetic study for patients with M. abscessus complex-PD. Patients, who are scheduled to initiate treatment for M. abscessus complex-PD between 1 January 2023 and 31 December 2024 at Seoul National University Hospital, will be the subject of study. The size of population is estimated to be 40.

Eligibility criteria: Inclusion Criteria:

* Age 20 years old or more
* Fulfilling the criteria of NTM-PD (1, 13), for which causative organism belongs to M. abscessus or M. massiliense
* Needing a new antibiotic treatment for M. abscessus complex-PD due to symptomatic aggravation, radiographic progression or both (those who have previous history of treatment are eligible)
* Consenting to receive antibiotic treatment based on currently recommended regimens (1, 13) and to participate in this study

Exclusion Criteria:

* Receiving any treatment for NTM-PD within 4 weeks
* Having end-stage renal disease needing hemodialysis, chronic liver disease, or active malignancy needing treatment during the treatment period

Primary outcomes:
measure: Peak concentration (Cmax)
timeFrame: 2 weeks of treatment
measure: Time to Cmax
timeFrame: 2 weeks of treatment
measure: Area under the curve from 0 to 24 hours after dosing
timeFrame: 2 weeks of treatment
measure: Plasma half-life
timeFrame: 2 weeks of treatment
Secondary outcomes:
measure: Time to culture positivity (days) by AUC24 (mg x h/L)
timeFrame: 2 weeks of treatment
measure: Time to culture positivity (days) by Cmax (mg /L)
timeFrame: 2 weeks of treatment
Other outcomes:
Locations:
Study officials:
affiliation: Seoul National University Hospital
name: Jae-Joon Yim, MD
role: PRINCIPAL_INVESTIGATOR
References: